SEEK

SEEK began life in 2004 as an immunology company, quickly establishing a new vaccine-technology platform with a focus on peptide-based T cell vaccines (derived from a novel understanding of the molecular-level interactions between immune cells). Lead products under this platform are a Universal Flu and an HIV vaccine, with Phase Ib/II clinical trial data due early and mid-2011, with vaccines for mosquito-transported and chagas diseases in the pre-clinical phase, and Hepatitis B & C and rotavirus vaccines in research.